NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
2.950
-0.080 (-2.64%)
At close: Apr 28, 2026, 4:00 PM EDT
2.930
-0.020 (-0.68%)
After-hours: Apr 28, 2026, 5:55 PM EDT
NRx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for NRx Pharmaceuticals stock have an average target of 38.25, with a low estimate of 25 and a high estimate of 49. The average target predicts an increase of 1,196.61% from the current stock price of 2.95.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRx Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 5 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +1,425.42% | Apr 27, 2026 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $48 → $49 | Strong Buy | Maintains | $48 → $49 | +1,561.02% | Apr 27, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,052.54% | Apr 23, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,052.54% | Apr 20, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,052.54% | Mar 24, 2026 |
Financial Forecast
Revenue This Year
32.44M
from 1.23M
Increased by 2,547.84%
Revenue Next Year
548.73M
from 32.44M
Increased by 1,591.73%
EPS This Year
0.31
from -1.34
EPS Next Year
1.19
from 0.31
Increased by 290.00%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 33.4M | 582.3M | ||||||
| Avg | 32.4M | 548.7M | ||||||
| Low | 31.2M | 511.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2,625.7% | 1,695.1% | ||||||
| Avg | 2,547.8% | 1,591.7% | ||||||
| Low | 2,444.0% | 1,475.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.32 | 1.23 | |
| Avg | 0.31 | 1.19 | |
| Low | 0.29 | 1.15 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | 301.5% | |
| Avg | - | 290.0% | |
| Low | - | 274.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.